格隆汇10月30日｜凯莱英(002821.SZ)发布2025年第三季度报告，第三季度实现营业收入14.42亿元，同 比下降0.09%；归属于上市公司股东的净利润为1.83亿元，同比下降13.46%。前三季度实现营业收入 46.30亿元，同比增长11.82%；归属于上市公司股东的净利润为8.00亿元，同比增长12.66%。 ...

凯莱英医药集团（天津）股份有限公司 2025 年第三季度报告 证券代码：002821 证券简称：凯莱英 公告编号：2025-064 凯莱英医药集团（天津）股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个 别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 2 凯莱英医药集团（天津）股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 1,441,570,606.55 | -0.09% | 4,629,877,130. ...

凯莱英公告，第三季度营收为14.42亿元，同比下降0.09%；净利润为1.83亿元，同比下降13.46%。前三 季度营收为46.3亿元，同比增长11.82%；净利润为8亿元，同比增长12.66%。 ...

Core Insights - The article highlights the diverse investment strategies of fund managers as they disclose their third-quarter reports for 2025, focusing on their portfolio adjustments and sector allocations [1][3]. Fund Manager Strategies - Fund managers are adopting varied investment strategies, with some focusing on long-term investments in the consumer market, while others are capitalizing on opportunities in the pharmaceutical and artificial intelligence sectors [3]. - The top three sectors with the highest allocation weights in the third-quarter reports are electronics (23.93%), power equipment and new energy (10.27%), and pharmaceuticals (9.81%) [3]. Notable Fund Performance - Zhang Kun's funds, including E Fund Blue Chip Select Mixed and E Fund Quality Select Mixed, saw net asset growth, with respective net growth rates of 16.37% and 17.58% in the third quarter [4][5]. - The largest fund managed by Zhang Kun, E Fund Blue Chip Select Mixed, replaced SF Express with Focus Media in its top ten holdings and increased positions in Kweichow Moutai and Baisheng China [4][5]. Pharmaceutical Sector Insights - Guo Lan, recognized as a leading figure in the medical sector, reported a net growth rate of 59.1% for her fund, with significant holdings in companies like Kanglong Chemical and Bai Li Tianheng [6][7]. - Guo Lan emphasized that quality and innovation are crucial trends in the pharmaceutical industry, with a focus on the synergy between enterprise innovation and supportive policies [7]. AI and Technology Focus - Xie Zhiyu's fund, Xingquan He Run, increased its investments in AI-related companies, adding four new top holdings in sectors like optical modules and PCB [8][9]. - The fund's net growth rate reached 36.16%, reflecting a strong performance amid a focus on AI and semiconductor investments [9]. Future Outlook - The article suggests that the global cloud computing industry remains a key area of focus, with AI models gaining value and driving new market opportunities [12][13]. - The anticipated growth in the AI computing sector is expected to create more opportunities across the industry chain, particularly in optical communication and PCB sectors [13].

Market Overview - A-shares showed mixed performance on October 30, with the Shanghai Composite Index rising by 0.06% and the Shenzhen Component Index and ChiNext Index declining by 0.02% and 0.23% respectively. The half-day trading volume reached 1.53 trillion yuan, an increase of 107.8 billion yuan compared to the previous trading day [1] Investment Focus - Current investment focus includes three main directions: technology growth as a core area, high-dividend defensive sectors, and cyclical sectors such as non-ferrous metals, chemicals, and steel as elastic supplements [1] Sector Performance - Quantum technology concept stocks surged, with Shenzhou Information achieving a six-day three-limit rise. Other stocks like Weide Information and Guodun Quantum also saw gains. This surge is attributed to NVIDIA's launch of NVQLink, which connects quantum computing with GPU computing [2] - The innovative drug and CRO sectors experienced declines, with WuXi AppTec dropping nearly 9%. This decline follows an announcement regarding a planned share reduction by major shareholders [3] Institutional Insights - Huatai Securities suggests a high probability of the index continuing to break upwards, driven by structural bull market characteristics and potential easing of negative market factors following US-China negotiations [4] - Huajin Securities maintains that a slow bull market and technology as the main line remain unchanged, recommending low-cost allocations in technology growth and certain cyclical sectors [5] - Everbright Securities anticipates continued upward movement in the market, with the Shanghai Composite Index surpassing 4000 points, potentially attracting more external funds [6]

Market Overview - The Hong Kong stock market is experiencing a shift in capital flow, moving from growth to a more defensive positioning amid a collective decline in the three major indices [1] - On October 28, the market failed to maintain the previous day's gains, with a trading volume of 242.7 billion HKD, indicating a cautious investor sentiment [1] Sector Performance - The gold sector faced significant declines, with multiple stocks experiencing steep drops: China Silver Group fell over 10%, Lingbao Gold down 5.74%, and Zijin Mining down 5.59% [3] - The drop in gold stocks is closely linked to the international gold price, which fell 3.05% on October 27, dropping below 3990 USD per ounce [3] - The new consumption sector, once favored, is now seeing substantial outflows, with leading stocks like Pop Mart down over 32% from their historical highs [6] - The technology sector also showed weakness, with major stocks like NetEase and Meituan declining by 2.35% and 1.96% respectively [8] Capital Flow - There has been a notable shift in capital flow, with southbound funds moving from net inflows to significant outflows in the consumer sector, redirecting towards technology and healthcare [8] - Despite the overall market downturn, local bank and insurance stocks performed well, with HSBC rising 4.41% due to better-than-expected quarterly results [10] Investment Sentiment - The market is witnessing a rotation from high-growth, high-valuation sectors to defensive assets, reflecting a change in investor risk appetite [10] - Continuous inflows from southbound funds, totaling 2.258 billion HKD on October 28, indicate mainland investors' recognition of the long-term value in Hong Kong stocks [12] Economic Outlook - Analysts suggest that potential interest rate cuts by the Federal Reserve and a depreciating USD alongside an appreciating RMB could support the valuation of Chinese assets, benefiting the Hong Kong market [14] - The significant pullback in gold stocks and the weakness in consumer stocks illustrate a clear picture of declining risk appetite in the current market environment [14]

Core Insights - The Biotech Economy Index (970038) closed at 2298.38 points, up 0.92%, with a trading volume of 24.11 billion yuan and a turnover rate of 1.39% [1] - Among the index constituents, 27 stocks rose while 22 fell, with Tigermed leading the gainers at 11.09% and Kaili Medical leading the decliners at 11.39% [1] Index Performance - The Biotech Economy Index had a net inflow of 169 million yuan from institutional investors, while retail investors experienced a net outflow of approximately 79.92 million yuan [1][2] - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, latest price 222.83 yuan, market cap 270.17 billion yuan) [1] - Changchun High-tech (5.41% weight, latest price 117.55 yuan, market cap 47.95 billion yuan) [1] - Kanglong Chemical (4.66% weight, latest price 34.05 yuan, market cap 60.55 billion yuan) [1] - Tigermed (4.23% weight, latest price 59.48 yuan, market cap 51.21 billion yuan) [1] - Other notable constituents include Deep Technology, Muyuan Foods, and Aimeike [1] Capital Flow Analysis - The capital flow details indicate that Deep Technology had a net inflow of 201 million yuan from institutional investors, while retail investors saw a significant outflow of 222 million yuan [2] - Kanglong Chemical and Tigermed also experienced net inflows from institutional investors, but faced outflows from retail investors [2] - Overall, the data suggests a mixed sentiment among different investor classes within the Biotech Economy Index [2]

Core Insights - The article highlights the significant changes in the stock positions of various funds managed by the company, particularly in the healthcare sector, indicating a strategic shift towards high-performing stocks [1] Group 1: Fund Performance - The stock position of the China Europe Medical Health fund reached a record high of 94.56% [1] - The China Europe Medical Innovation fund significantly increased its holdings in Kanglong Chemical [1] Group 2: Stock Adjustments - The China Europe Medical Health fund made its first purchase of Haisco and increased its holdings in Kanglong Chemical, Baillie Gifford, Kylin Pharmaceutical, Tigermed, and Xinlitai [1] - The China Europe Medical Innovation fund reduced its positions in several stocks, including 3SBio and Kanyin Biotech [1] - The China Europe Mingrui New Starting Point fund increased its investments in Yangguang Electric, New Yisheng, Zhongji Xuchuang, Tianfu Communication, Hanwha, and Industrial Fulian [1]

Core Points - The Bioeconomy Index (970038) closed at 2277.51 points, down 0.16%, with a trading volume of 18.883 billion yuan and a turnover rate of 1.2% [1] - Among the index constituents, 23 stocks rose while 27 fell, with Iwubio leading the gainers at 6.71% and Meiya Optoelectronics leading the decliners at 3.02% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 225.09 yuan, and a market cap of 272.908 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 116.50 yuan, and a market cap of 47.525 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.97 yuan, and a market cap of 56.849 billion yuan [1] - Other notable constituents include Shishihistory (sz002252), Table Pharmaceutical (sz300347), and Muyuan Foods (sz002714) [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 871 million yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [3] - Key capital flows include: - Iwubio (300357) with a net inflow of 52.9277 million yuan from institutional investors [3] - Dabo Medical (002901) with a net inflow of 31.8434 million yuan from institutional investors [3] - Changchun High-tech (000661) with a net inflow of 27.6452 million yuan from institutional investors [3]

Core Viewpoint - WuXi AppTec plans to sell two clinical service subsidiaries, Kangde Hongyi and Jinshi Pharmaceutical, to Hillhouse Capital for a base price of 2.8 billion yuan, as part of its strategy to focus on its core CRDMO business [1][4][8] Financial Performance - For the first three quarters of 2025, the combined revenue of Kangde Hongyi and Jinshi Pharmaceutical was approximately 1.16 billion yuan, accounting for 3.5% of WuXi AppTec's total revenue [5] - The net profit of these subsidiaries was about 90 million yuan, representing 0.7% of the company's net profit for the same period [5] - WuXi AppTec reported a total revenue of 32.857 billion yuan for the first three quarters of 2025, a year-on-year increase of 18.61%, with a net profit of 12.076 billion yuan, up 84.84% [6][7] Business Strategy - The sale of the subsidiaries is part of WuXi AppTec's strategy to concentrate on drug discovery, laboratory testing, and production, while accelerating global capacity expansion [5][8] - The company aims to optimize its financial structure and respond to industry challenges, including increased competition and pricing pressures from peers [9] Market Dynamics - WuXi AppTec's revenue from the U.S. market was 22.15 billion yuan, a year-on-year increase of 31.9%, while revenue from the Chinese market grew only 0.5% [6] - The company has been adjusting its strategy in response to external risks, including the U.S. Biosecurity Act, which has raised concerns about its operations [8][9]